Dova Pharmaceuticals Revenue and Competitors

Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova's lead drug product, Avatrombopag, indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure, was US FDA approved in May 2018 and subsequently launched in the US commercial market in June 2018. Headquartered in Durham, NC, Dova continues to build its teams, resulting in our hiring needs. With a nimble approach and a team of bright minds aglow with passion, we're dedicated to bringing brilliant medicine to market. With a deeply skilled management team directing our day-to-day wins, and a Board with a stellar track record, we're ready to take on the world's diseases, ailments and adversity. Our people believe they have the power to make a positive impact in others lives because that's exactly what we do here. If you're seeking a career that taps into your talents in a way that makes the world a better, healthier place, we just may have a job for you.